Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact | Frank Vinluan | 08/07/20 | Boston |
Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D | Sarah de Crescenzo | 07/30/20 | San Francisco |
Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds | Sarah de Crescenzo | 06/22/20 | Boston |
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes | Frank Vinluan | 06/11/20 | Boston |
Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact | Frank Vinluan | 06/01/20 | New York |
Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments | Sarah de Crescenzo | 05/26/20 | San Diego |
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic | Frank Vinluan | 02/18/20 | Boston |
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts | Frank Vinluan | 02/10/20 | Boston |
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered | Sarah de Crescenzo | 02/06/20 | Boston |
Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits | Frank Vinluan | 01/22/20 | New York |
Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D | Frank Vinluan | 01/15/20 | New York |
A Safer CRISPR? Cyrus, Broad Institute Look to Quell Concerns | Melissa Fassbender | 12/03/19 | National |
Global Blood’s Sickle Cell Drug Wins FDA Approval Ahead of Schedule | Frank Vinluan | 11/25/19 | San Francisco |
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More | Frank Vinluan | 11/08/19 | National |
eGenesis Lands $100M to Advance CRISPR-ed Pig Kidney to Human Test | Frank Vinluan | 11/07/19 | Boston |
ArsenalBio Launches With $85M for “Programmable” T Cell Therapies | Frank Vinluan | 10/17/19 | San Francisco |
Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System | Frank Vinluan | 09/10/19 | San Francisco |
Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes | Frank Vinluan | 09/03/19 | Boston |
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More | Alex Lash | 08/30/19 | National |
Inari Reaps $89M and Eyes Global Farm Markets for Gene-Edited Seeds | Frank Vinluan | 08/06/19 | Boston |
GlycoMimetics Sickle Cell Drug Flops as Others Creep Forward | Ben Fidler | 08/05/19 | New York |
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More | Alex Lash | 07/12/19 | National |
Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA | Sarah de Crescenzo | 06/21/19 | San Diego |
Study: Gene Edits in CRISPR Babies Could Boost Risk of Earlier Death | Alex Lash | 06/03/19 | National |
Verve Has Top Cardio-Geneticist, $58.5M to Aim CRISPR at Heart Attacks | Alex Lash | 05/07/19 | Boston |
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More | Ben Fidler | 04/19/19 | National |
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M | Ben Fidler | 03/21/19 | Boston |